Tolremo Therapeutics AG. (6/22/22). "Press Release: Tolremo Therapeutics AG Announces Appointment of Dr. Karl Schumacher as Chief Medical Officer". Muttenz.

	Organisation	Tolremo Therapeutics AG
	Organisation 2	Merck KGaA
	Group	Merck (DE) (Group)
	Product	TT125-082 (Tolremo Therapeutics)
	Product 2	DNA Damage Response (DDR) cancer therapy
	Person	Schumacher, Karl (Tolremo Therapeutics 202206– CMO before Merck KGaA)
	Person 2	Flückiger-Mangual, Stefanie (201809 CEO + Co-Founder)

TOLREMO therapeutics AG today announced that Dr. Karl Schumacher, MD, MHBA, has joined the company as Chief Medical Officer (CMO). Dr. Schumacher will lead the clinical and medical programs of TOLREMO in support of the company’s lead asset TT125-802, that is expected to enter the clinic in early 2023. He will help in the further advancement of TOLREMO’s platform, addressing the unmet medical need of non-genetic cancer drug resistance.

«We are delighted to have Karl join TOLREMO’s executive management team in this exciting phase for the company. With more than 10 years of clinical development experience in oncology focusing on combination therapies and drug resistance, he will add tremendous value to our drug development programs» said Dr. Stefanie Flückiger-Mangual, CEO and co-founder of TOLREMO.

Dr. Schumacher practiced surgical oncology for several years before joining the life sciences industry. Prior to joining TOLREMO, he held various roles in the pharmaceutical industry focusing on drug combinations to prevent resistance to targeted therapies in multiple cancer types. He has been instrumental to the clinical development of targeted and innovative anti-cancer therapies for NSCLC, breast cancer and melanoma. He joins TOLREMO from Merck KGaA where he was Vice President Clinical Development for the MET inhibitor tepotinib (Tepmetko®) and the DNA damage response (DDR) inhibitor portfolio.

«I am excited to join TOLREMO at this pivotal phase of the company’s development. I am looking forward to applying my clinical expertise with drug combinations and cancer drug resistance to the company’s clinical development. I am convinced that TT125-802 has a high potential to be developed as a versatile combination partner to a number of targeted therapies» said Dr. Karl Schumacher.

About TOLREMO

TOLREMO therapeutics AG is a Switzerland-based preclinical biotechnology company founded in 2017 by leading experts in the field of cancer drug resistance. The company leverages a proprietary technology platform to develop small molecules that when combined with targeted cancer agents prevent non-genetic drug resistance. The company’s lead candidate TT125-802 shows promising activity in sophisticated preclinical models as combination therapy in the prevention of cancer drug resistance in CRC and NSCLC harboring specific mutations, including KRAS. Preclinical monotherapy activity has been shown for selected solid tumors and hematological malignancies. The compound bears the potential of broad relevance in several cancer indications where standard of care treatments are currently limited by the rapid development of resistance. TOLREMO’s platform aims to deliver therapies to complement standard cancer therapies to offer better response rates, longer survival and an improved quality of life to patients with cancer. To learn more, visit www.tolremo.com.

For further details, please contact:

Dr. Stefanie Flückiger-Mangual, CEO and co-founder
stefanie.flueckiger@tolremo.com

TOLREMO therapeutics AG I Hofackerstrasse 40B I 4132 Muttenz I Switzerland
www.tolremo.com

Record changed: 2023-06-05